1Selwyn AP.Prothrombotic and antithrombotic pathways in acute coronary syndromes.Am J Cardiol,2003,91:3H-11H.
2Eikelboom JW,Hirsh J,Weitz JI,et al.Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction,stroke,or cardiovascular death in patients at high risk for cardiovascular events.Circulation,2002,105:1650-1655.
3Muller I,Besta F,Schulz C,et al.Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.Thromb Haemost,2003,89:783-787.
4Soffer D,Moussa I,Harjai KJ,et al.Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention:do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv,2003,59:21-25.
5Aleil B,Ravanat C,Cazenave JP,et al.Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.J Thromb Haemost,2005,3:85-92.
6Serebruany VL,Steinhubl SR,Berger PB,et al.Variability in platelet responsiveness to clopidogrel among 544 individuals.J Am Coll Cardiol,2005,45:246-251.
7Woulfe D,Yang J,Brass L.ADP and platelets:the end of the beginning.J Clin Invest,2001,107:1503-1505.
9Conley PB,Delaney SM.Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis.Curr Opin Hematol,2003,10:333-338.
10Ding Z,Kim S,Dorsam RT,et al.Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues,Cys17 and Cys270.Blood,2003,101:3908-3914.
